Dendreon Reports More Positive Data

4/20/09

Seattle-based biotech firm Dendreon (NASDAQ:DNDN) yesterday reported data from an ongoing Phase III clinical trial of its drug sipuleucel-T (Provenge), saying that the drug caused long-term immune responses in patients with recurrent prostate cancer and whose prostates have been surgically removed. The data follows Dendreon’s whirlwind last week when shares of the company’s stock soared after it revealed that Provenge could prolong life of patients with prostate cancer with few side effects. Dendron’s stock was up 6.5 percent to $19.15 per share at 12:33 pm Eastern.

By posting a comment, you agree to our terms and conditions.